Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...

When we think about the immune system, we usually associate it with fighting infections. However, a study published in Science by the Champalimaud Foundation reveals a surprising new role.

Glucagon-like peptide 1 receptor agonists (GLP1RA)-medications for type 2 diabetes and obesity that have recently been making headlines due to a rise ...

Scientists may have identified a way to naturally regulate blood sugar levels and sugar cravings in a similar fashion to ...

The study proposes the immune system as a major regulator of blood sugar. The functions of hormones like insulin and glucagon ...

Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on ...

Findings suggest targeting neuro-immune pathway could lead to strategies for managing diabetes, obesity or some types of ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing dozens of health conditions. But the semaglutide-like drugs also appear to ...

Coya Therapeutics, Inc. (NASDAQ:COYA) announced the expansion of its investigational pipeline and advancement of COYA 303 for ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have been ...